Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.60 |
| ▸ | TSHR | P16473 | 7/20 | 0.60 |
| ▸ | HPGD | P15428 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 2/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13623675 | 0.89 | HSD17B10 (0.60) | HSD17B10TSHRHPGDALDH1A1CYP3A4 | |
| SCHEMBL15149919 | 0.86 | HSD17B10 (0.48) | HSD17B10TSHRHPGDALDH1A1CYP3A4 | |
| SCHEMBL4306430 | 0.82 | CYP3A4 (0.35) | HSD17B10TSHRHPGDALDH1A1CYP3A4 | |
| SCHEMBL48305 | 0.82 | HSD17B10 (0.86) | HSD17B10TSHRHPGDALDH1A1CYP3A4 | |
| SCHEMBL10825844 | 0.80 | HSD17B10 (0.55) | HSD17B10TSHRHPGDALDH1A1CYP3A4 | |
| Triclofenol SCHEMBL1338 | 0.76 | HSD17B10 (1.00) | HSD17B10TSHRHPGDALDH1A1CYP3A4 | |
| SCHEMBL592892 | 0.76 | HSD17B10 (0.75) | HSD17B10TSHRHPGDALDH1A1CYP3A4 | |
| SCHEMBL1436824 | 0.76 | AHR (0.44) | HSD17B10TSHRHPGDALDH1A1CYP3A4 | |
| Triclofenol SCHEMBL29387498 | 0.76 | HSD17B10 (1.00) | HSD17B10TSHRHPGDALDH1A1CYP3A4 | |
| SCHEMBL6518998 | 0.73 | AHR (0.42) | HSD17B10TSHRHPGDCYP3A4CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054912-A1 | Modulators of acetylcholine receptors | ASTLES PETER C | 2007-03-08 | — | — | US | disclosed |
| US-7148236-B2 | Modulators of acetylcholine receptors | MERCK & CO., INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20050182088-A1 | Modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-08-18 | — | — | US | disclosed |
| EP-1472248-A1 | MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003062235-A1 | MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182088-A1 | Modulators of acetylcholine receptors | CHRM3, CHRNG, CHRM5 | HSD17B10 1779/4885TSHR 59/4885HPGD 910/4885 |
| US-20070054912-A1 | Modulators of acetylcholine receptors | CHRM3, CHRNG, CHRM5 | HSD17B10 2070/4885TSHR 82/4885HPGD 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.